A combination of poly(ADP-ribose) polymerase (PARP) inhibitors with PD-L1 inhibitor (olaparib + durvalumab) has also been tested, with results showing improved efficacies of combination treatments in germline BRCA-mutated platinum-sensitive relapsed ovarian cancer patients [35] and patients with relapsed gastric cancer [36] in the MEDIOLA study. This evidence concerns the gene CD274 and ovarian carcinoma.